ASH 2011 - San Diego - CML - Chronic Myeloid Leukemia
Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts
December 2, 2011, Reuters
2011 ASH Annual Meeting to Highlight Latest Hematology Research, Clinical Care Breakthroughs
December 1, 2011, PRNewswire
National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting
December 1, 2011, Physorg.com
December 2, 2011, Reuters
2011 ASH Annual Meeting to Highlight Latest Hematology Research, Clinical Care Breakthroughs
December 1, 2011, PRNewswire
National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting
December 1, 2011, Physorg.com
CML Program
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy
Includes basic studies of any aspect of CML, including pre-clinical and animal models of drug therapy, biological agents, immunotherapy and vaccine development as well as pathophysiology at cellular or molecular levels.
632. Chronic Myeloid Leukemia: Therapy
Includes diagnosis, prognosis, therapy, epidemiology, complications, follow-up, quality of life, and socioeconomic aspects. For comparative trials of treatment regimens versus transplantation, see category 731.
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy
Includes basic studies of any aspect of CML, including pre-clinical and animal models of drug therapy, biological agents, immunotherapy and vaccine development as well as pathophysiology at cellular or molecular levels.
632. Chronic Myeloid Leukemia: Therapy
Includes diagnosis, prognosis, therapy, epidemiology, complications, follow-up, quality of life, and socioeconomic aspects. For comparative trials of treatment regimens versus transplantation, see category 731.
Reporting Live from ASH 2011 by the CML Society of Canada
ASH 2011: Summary of Education Session on CML by CML Advocates Network
ASH 2011 Report: Key news on CML from a patients' perspective by CML Advocates Network
ASH NEWS DAILY – Ernest Beutler Lectures Work Toward CML Cure with Dr. Janet Rowley and Dr. Brian Druker
ASH 2011: Summary of Education Session on CML by CML Advocates Network
ASH 2011 Report: Key news on CML from a patients' perspective by CML Advocates Network
ASH NEWS DAILY – Ernest Beutler Lectures Work Toward CML Cure with Dr. Janet Rowley and Dr. Brian Druker
FORUMS
Leukemia & Lymphomna Society :ASH2011- General
Myelosuppression: ASH 2011 - LLS
ASH 2011 - CML EDUCATION TKI Therapy for CML Dr. Neil Shah (New CML Drug.com)
Leukemia & Lymphomna Society :ASH2011- General
Myelosuppression: ASH 2011 - LLS
ASH 2011 - CML EDUCATION TKI Therapy for CML Dr. Neil Shah (New CML Drug.com)
VIDEOS
Brian Druker: My Vision for CML and the Road to a Cure by Patient Power
Jorges Cortes: Two New Winners for CML? by Medscape News Today
Early Treatment for CML: A Closer Watch and Newer Options by Patient Power
TWITTER
ASH2011
ASH11
Brian Druker: My Vision for CML and the Road to a Cure by Patient Power
Jorges Cortes: Two New Winners for CML? by Medscape News Today
Early Treatment for CML: A Closer Watch and Newer Options by Patient Power
ASH2011
ASH11
ASH2011 NEWS
ASH: Bone Marrow Best for Unrelated Donor SCT
HyperCVAD Plus Dasatinib Effective in Patients with Ph+ ALL or CML-LB
Ariad Cancer Drug Positive Trial May Boost Approval Chances
Onyx Trips, Ariad and Pharmacyclics Shine at Blood Cancer Meeting
BELA Trial: Bosutinib May Be Superior to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
More news for ASH meeting
Nilotinib shows promise as first-line therapy in CML
BELA Trial: Bosutinib bested imatinib in patients with chronic CML (featuring Dr. Cortes)
ENEST: Patients with Ph+CML exhibited deeper responses to nilotinib than imatinib mesylate
CML updatde from 2011 ASH annual meeting
5 Winners Of American Society Of Hematology 2011
Promising treatments for blood cancers presented by JTCancerCenter researchers at ASH meeting
Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease
Velcade-Belinostat Combination May Be Active In Myelodysplastic Syndromes (ASH 2011)
ASH: Bone Marrow Best for Unrelated Donor SCT
HyperCVAD Plus Dasatinib Effective in Patients with Ph+ ALL or CML-LB
Ariad Cancer Drug Positive Trial May Boost Approval Chances
Onyx Trips, Ariad and Pharmacyclics Shine at Blood Cancer Meeting
BELA Trial: Bosutinib May Be Superior to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
More news for ASH meeting
Nilotinib shows promise as first-line therapy in CML
BELA Trial: Bosutinib bested imatinib in patients with chronic CML (featuring Dr. Cortes)
ENEST: Patients with Ph+CML exhibited deeper responses to nilotinib than imatinib mesylate
CML updatde from 2011 ASH annual meeting
5 Winners Of American Society Of Hematology 2011
Promising treatments for blood cancers presented by JTCancerCenter researchers at ASH meeting
Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease
Velcade-Belinostat Combination May Be Active In Myelodysplastic Syndromes (ASH 2011)
December 12, 2011 1:30 PM-2:30 PM
San Diego Convention Center (Hall AB)
"Chronic myeloid leukemia (CML) was virtually uniformly fatal before the late 1990s with a median survival of about three years. In 1960, a unique small marker chromosome called the Philadelphia (Ph1) chromosome was identified. In 1973, it was determined to be a translocation that led to a fusion of the involved genes on chromosomes 9 and 22; the gene on 9 was the Abelson (ABL) oncogene, a known tyrosine kinase. This knowledge led to the development of an inhibitor of the ABL tyrosine kinase that specifically killed cultured CML cells. Clinical trials confirmed these pre-clinical observations and this oral drug, imatinib (Gleevec or STI571), has revolutionized treatment with five-year survival rates of almost 90 percent. Thus, although it took 40 years, CML is a story of success, from the identification of a unique genetic change to the development of a remarkably effective genetically targeted therapy. Dr. Janet Rowley will discuss the discovery of the chromosome translocations and cloning of the translocation breakpoint. Dr. Brian Druker will discuss the pre-clinical and clinical development of ABL inhibitors, including the problem of resistance."
Chair(s):
Janet D. Rowley, MD Brian J. Druker, MD
Univ. of Chicago Med. Ctr. OHSU Knight Cancer Institute
Chicago, IL, USA Portland, OR, USA
ASH NEWS DAILY – Ernest Beutler Lectures Work Toward CML Cure with Dr. Janet Rowley and Dr. Brian
